MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

TG Therapeutics Inc

Open

BrancheGesundheitswesen

40.81 1.64

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

39.33

Max

41.01

Schlüsselkennzahlen

By Trading Economics

Einkommen

19M

23M

Verkäufe

24M

108M

KGV

Branchendurchschnitt

246.467

57.333

EPS

0.15

Gewinnspanne

21.566

Angestellte

338

EBITDA

17M

33M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+6.7% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

30. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

912M

5.8B

Vorheriger Eröffnungskurs

39.17

Vorheriger Schlusskurs

40.81

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

TG Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Aug. 2024, 20:01 UTC

Ergebnisse

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Peer-Vergleich

Kursveränderung

TG Therapeutics Inc Prognose

Kursziel

By TipRanks

6.7% Vorteil

12-Monats-Prognose

Durchschnitt 43 USD  6.7%

Hoch 55 USD

Tief 11 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für TG Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

5

Buy

0

Halten

1

Sell

Technischer Score

By Trading Central

38.41 / 40.35Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.